Figure 6
From: Keratin 19 regulates cell cycle pathway and sensitivity of breast cancer cells to CDK inhibitors
K19-dependent expression of cyclins and CDKs. (a) Whole cell lysates of P, KO1, and KO2 cells were harvested, and immunoblotting was performed with antibodies against the indicated proteins. (b) Signal intensities of cyclins from (a) were quantified and normalized to those of the GAPDH loading control. Data from at least three experimental repeats normalized to that of the parental control are shown as mean ± SEM. Differences are not statistically significant unless denoted by *p < 0.05; **p < 0.001. (c) Whole cell lysates of KRT19 KO cells expressing vector (V) or K19 (K19) were harvested, and immunoblotting was performed with antibodies against the indicated proteins. (d) Signal intensities of bands from (c) were quantified and normalized to those of GAPDH loading control. Data from at least three experimental repeats normalized to that of the parental control are shown as mean ± SEM. Differences are not statistically significant unless denoted by *p < 0.05; **p < 0.001. Tissue sections from 21 differerent breast cancer patients with most aggressive tumors were immunostained for (e) K19 and cyclin D1 or (f) K19 and cyclin D3. The immunoreactivity of cells in both the invasive tumor and adjacent benign epithelium in each case were scored and categorized as shown in Supplementary Tables S6 and 7. Those that were strongly positive in both K19 and cyclin D1 or cyclin D3 were separated from cases that were not (others).
